| 前收市價 | 745.69 |
| 開市 | 752.64 |
| 買盤 | 0.00 x 1000 |
| 賣出價 | 724.50 x 1100 |
| 今日波幅 | 728.78 - 752.64 |
| 52 週波幅 | 380.77 - 800.78 |
| 成交量 | |
| 平均成交量 | 3,063,427 |
| 市值 | 696.151B |
| Beta 值 (5 年，每月) | 0.37 |
| 市盈率 (最近 12 個月) | 126.68 |
| 每股盈利 (最近 12 個月) | 5.78 |
| 業績公佈日 | 2024年4月30日 |
| 遠期股息及收益率 | 5.20 (0.71%) |
| 除息日 | 2024年2月14日 |
| 1 年預測目標價 | 826.94 |
ZacksWill Healthcare ETFs Lose Momentum as Q1 Earnings Unfold?
While the healthcare sector is expected to benefit from cutting-edge medicines, new drug approvals, technological advancements, and deal activities, it is expected to witness a modest earnings decline of 5.6% in the first quarter.
Zacks4 Large Drug Stocks to Hold on to Amid Industry Challenges
Drug and biotech companies are likely to see significant innovation. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), Merck (MRK) and AbbVie (ABBV) are worth retaining in one's portfolio.
ZacksAnalysts Estimate Pfizer (PFE) to Report a Decline in Earnings: What to Look Out for
Pfizer (PFE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
